The Management of Biliary Disease in Patients with Severe Obesity Undergoing Metabolic and Bariatric Surgery-An International Expert Survey.
Cholecystolithiasis
Choledocholithiasis
Cholelithiasis
Common bile duct stones
Endoscopic retrograde cholangiopancreatography
Gallstone disease
Gallstones
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
24 Feb 2024
24 Feb 2024
Historique:
received:
20
12
2023
accepted:
15
02
2024
revised:
09
02
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
aheadofprint
Résumé
This study aimed to survey international experts in metabolic and bariatric surgery (MBS) to improve and consolidate the management of biliary disease in patients with severe obesity undergoing MBS. Obesity and rapid weight loss after MBS are risk factors for the development of gallstones. Complications, such as cholecystitis, acute cholangitis, and biliary pancreatitis, are potentially life-threatening, and no guidelines for the proper management of gallstone disease exist. An international scientific team designed an online confidential questionnaire with 26 multiple-choice questions. The survey was answered by 86 invited experts (from 38 different countries), who participated from August 1, 2023, to September 9, 2023. Two-thirds of experts (67.4%) perform concomitant cholecystectomy in symptomatic gallstones during MBS. Half of experts (50%) would wait 6-12 weeks between both surgeries with an interval approach. Approximately 57% of the experts prescribe ursodeoxycholic acid (UDCA) prophylactically after MBS, and most recommend a 6-month course. More than the half of the experts (59.3%/53.5%) preferred laparoscopic assisted transgastric ERCP as the approach for treating CBD stones in patients who previously had RYGB/OAGB. Concomitant cholecystectomy is preferred by the experts, although evidence in the literature reports an increased complication rate. Prophylactic UDCA should be recommended to every MBS patient, even though the current survey demonstrated that not all experts are recommending it. The preferred approach for treating common bile duct stones is a laparoscopic assisted transgastric ERCP after gastric bypass. The conflicting responses will need more scientific work and clarity in the future.
Sections du résumé
OBJECTIVE
OBJECTIVE
This study aimed to survey international experts in metabolic and bariatric surgery (MBS) to improve and consolidate the management of biliary disease in patients with severe obesity undergoing MBS.
BACKGROUND
BACKGROUND
Obesity and rapid weight loss after MBS are risk factors for the development of gallstones. Complications, such as cholecystitis, acute cholangitis, and biliary pancreatitis, are potentially life-threatening, and no guidelines for the proper management of gallstone disease exist.
METHODS
METHODS
An international scientific team designed an online confidential questionnaire with 26 multiple-choice questions. The survey was answered by 86 invited experts (from 38 different countries), who participated from August 1, 2023, to September 9, 2023.
RESULTS
RESULTS
Two-thirds of experts (67.4%) perform concomitant cholecystectomy in symptomatic gallstones during MBS. Half of experts (50%) would wait 6-12 weeks between both surgeries with an interval approach. Approximately 57% of the experts prescribe ursodeoxycholic acid (UDCA) prophylactically after MBS, and most recommend a 6-month course. More than the half of the experts (59.3%/53.5%) preferred laparoscopic assisted transgastric ERCP as the approach for treating CBD stones in patients who previously had RYGB/OAGB.
CONCLUSION
CONCLUSIONS
Concomitant cholecystectomy is preferred by the experts, although evidence in the literature reports an increased complication rate. Prophylactic UDCA should be recommended to every MBS patient, even though the current survey demonstrated that not all experts are recommending it. The preferred approach for treating common bile duct stones is a laparoscopic assisted transgastric ERCP after gastric bypass. The conflicting responses will need more scientific work and clarity in the future.
Identifiants
pubmed: 38400945
doi: 10.1007/s11695-024-07101-y
pii: 10.1007/s11695-024-07101-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Edo Aaarts
(E)
Imran Abbas
(I)
Ebrahim Aghajani
(E)
Luigi Angrisani
(L)
Luciano Antozzi
(L)
Jan Apers
(J)
Tanseer Asghar
(T)
Ahmad Bashir
(A)
Estuardo Behrens
(E)
Helmuth Billy
(H)
Daniel Caina
(D)
Miguel-A Carbajo
(MA)
Benjamin Clapp
(B)
Ricardo Cohen
(R)
Jerome Dargent
(J)
Amirhossein Davarpanah Jazi
(A)
Maurizio De Luca
(M)
Mohamad Hayssam ElFawal
(MH)
Daniel Moritz Felsenreich
(DM)
Michael Gagner
(M)
Pierre Garneau
(P)
Khaled Gawdat
(K)
Tikfu Gee
(T)
Omar M Ghanem
(OM)
Bijan Ghavami
(B)
Saber Ghiassi
(S)
Tamer A A M Habeeb
(TAAM)
Ashraf Haddad
(A)
Miguel F Herrera
(MF)
Farah Husain
(F)
Kazunori Kasama
(K)
Radwan Kassir
(R)
Nesreen Khidir
(N)
Mousa Khoursheed
(M)
Haris Khwaja
(H)
Lillian Kow
(L)
Jon Kristinsson
(J)
Matthew Kroh
(M)
Kuldeepak Singh Kular
(KS)
Panagiotis Lainas
(P)
Laurant Layani
(L)
Ken Loi
(K)
Kamal Mahawar
(K)
Tarek Mahdy
(T)
John Melissas
(J)
Karl Miller
(K)
Hazem Almomani
(H)
Mario Musella
(M)
Alexandr Neimark
(A)
Abdelrahman Nimeri
(A)
Patrick Noel
(P)
Taryel Omarov
(T)
Mariano Palermo
(M)
Chetan Parmar
(C)
Abdolreza Pazouki
(A)
Ralph Peterli
(R)
Tadeja Pintar
(T)
Tigran Poghosyan
(T)
Jaime Ponce
(J)
Dimitri Pournaras
(D)
Arun Prasad
(A)
Aayad Alqahtani
(A)
Almino Ramos
(A)
Masoud Rezvani
(M)
Karl Rheinwalt
(K)
Rui Ribeiro
(R)
Elena Ruiz-Ucar
(E)
Bassem Safadi
(B)
Nasser Sakran
(N)
Alaa Sewafy
(A)
Asim Shabbir
(A)
Shahab Shahabi Shahmiri
(SS)
Erik Stenberg
(E)
Halit Eren Taskin
(HE)
Antonio Torres
(A)
Cunchuan Wang
(C)
Sylvia Weiner
(S)
Wah Yang
(W)
Natan Zundel
(N)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Unalp-Arida A, Der JS, Ruhl CE. Longitudinal study of comorbidities and clinical outcomes in persons with gallstone disease using electronic health records. J Gastrointest Surg. 2023;27(12):2843–56.
doi: 10.1007/s11605-023-05861-z
pubmed: 37914859
Boerlage TCC, Haal S, Maurits de Brauw L, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery: study protocol for a randomized controlled trial (UPGRADE trial). BMC Gastroenterol. 2017;17(1):164.
doi: 10.1186/s12876-017-0674-x
pubmed: 29262795
pmcid: 5738131
Clapp B, Lee I, Liggett E, et al. Are concomitant operations during bariatric surgery safe? An analysis of the MBSAQIP Database. Obes Surg. 2020;30(11):4474–81.
doi: 10.1007/s11695-020-04848-y
pubmed: 32712783
Amorim-Cruz F, Santos-Sousa H, Ribeiro M, et al. Risk and prophylactic management of gallstone disease in bariatric surgery: a systematic review and a Bayesian meta-analysis. J Gastrointest Surg : Off J Soc Surg Aliment Tract. 2023;27(2):433–48.
doi: 10.1007/s11605-022-05567-8
Doulamis IP, Michalopoulos G, Boikou V, et al. Concomitant cholecystectomy during bariatric surgery: the jury is still out. Am J Surg. 2019;218(2):401–10.
doi: 10.1016/j.amjsurg.2019.02.006
pubmed: 30791992
Coogan AC, Williams MD, Krishnan V, et al. Ursodiol prescriptions following bariatric surgery: national prescribing trends and outcomes. Obes Surg. 2023;33(8):2361–7.
doi: 10.1007/s11695-023-06710-3
pubmed: 37392353
Mulliri A, Menahem B, Alves A, et al. Ursodeoxycholic acid for the prevention of gallstones and subsequent cholecystectomy after bariatric surgery: a meta-analysis of randomized controlled trials. J Gastroenterol. 2022;57(8):529–39.
doi: 10.1007/s00535-022-01886-4
pubmed: 35704084
Haal S, Guman MSS, Boerlage TCC, et al. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial. Lancet Gastroenterol Hepatol. 2021;6(12):993–1001.
doi: 10.1016/S2468-1253(21)00301-0
pubmed: 34715031
Yuan S, Gill D, Giovannucci EL, et al. Obesity, type 2 diabetes, lifestyle factors, and risk of gallstone disease: a Mendelian randomization investigation. Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc. 2022;20(3):e529–37.
doi: 10.1016/j.cgh.2020.12.034
Anveden Å, Peltonen M, Näslund I, et al. Long-term incidence of gallstone disease after bariatric surgery: results from the nonrandomized controlled Swedish Obese Subjects study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(10):1474–82.
doi: 10.1016/j.soard.2020.05.025
Kumaravel A, Zelisko A, Schauer P, et al. Acute pancreatitis in patients after bariatric surgery: incidence, outcomes, and risk factors. Obes Surg. 2014;24(12):2025–30.
doi: 10.1007/s11695-014-1337-4
pubmed: 24972683
Benarroch-Gampel J, Lairson DR, Boyd CA, et al. Cost-effectiveness analysis of cholecystectomy during Roux-en-Y gastric bypass for morbid obesity. Surgery. 2012;152(3):363–75.
doi: 10.1016/j.surg.2012.06.013
pubmed: 22938897
Yildirim K, Karabicak I, Gursel MF, et al. The outcome of concomitant cholecystectomy with bariatric surgery: a retrospective cohort study. Ann Med Surg (2012). 2023;85(4):718–21.
doi: 10.1097/MS9.0000000000000339
Leyva-Alvizo A, Arredondo-Saldaña G, Leal-Isla-Flores V, et al. Systematic review of management of gallbladder disease in patients undergoing minimally invasive bariatric surgery. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2020;16(1):158–64.
doi: 10.1016/j.soard.2019.10.016
Dirnberger AS, Schneider R, Slawik M, et al. Management of gallstone disease prior to and after metabolic surgery: a single-center observational study. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(2):182–8.
doi: 10.1016/j.soard.2021.10.006
Wood SG, Kumar SB, Dewey E, et al. Safety of concomitant cholecystectomy with laparoscopic sleeve gastrectomy and gastric bypass: a MBSAQIP analysis. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2019;15(6):864–70.
doi: 10.1016/j.soard.2019.03.004
de Lucena AVS, Cordeiro GG, Leão LHA, et al. Cholecystectomy concomitant with bariatric surgery: safety and metabolic effects. Obes Surg. 2022;32(4):1093–102.
doi: 10.1007/s11695-022-05889-1
pubmed: 35064462
Habeeb T, Kermansaravi M, Giménez ME, et al. Sleeve gastrectomy and cholecystectomy are safe in obese patients with asymptomatic cholelithiasis. A Multicenter Randomized Trial. World J Surg. 2022;46(7):1721–33.
doi: 10.1007/s00268-022-06557-2
pubmed: 35397750
pmcid: 9174306
Allatif REA, Mannaerts GHH, Al Afari HST, et al. Concomitant cholecystectomy for asymptomatic gallstones in bariatric surgery-safety profile and feasibility in a large tertiary referral bariatric center. Obes Surg. 2022;32(2):295–301.
doi: 10.1007/s11695-021-05798-9
pubmed: 34791618
Cunningham RM, Jones KT, Kuhn JE, et al. Asymptomatic cholelithiasis and bariatric surgery: a comprehensive long-term analysis of the risks of biliary disease in patients undergoing primary Roux-en-Y gastric bypass. Obes Surg. 2021;31(3):1249–55.
doi: 10.1007/s11695-020-05125-8
pubmed: 33230759
Xia C, Wang M, Lv H, et al. The safety and necessity of concomitant cholecystectomy during bariatric surgery in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2021;31(12):5418–26.
doi: 10.1007/s11695-021-05713-2
pubmed: 34564789
Elgohary H, El Azawy M, Elbanna M, et al. Concomitant versus delayed cholecystectomy in bariatric surgery. J Obes. 2021;2021:9957834.
doi: 10.1155/2021/9957834
pubmed: 34234964
pmcid: 8216831
Ohta M, Tada K, Endo Y, et al. Port-sharing techniques for laparoscopic cholecystectomy and sleeve gastrectomy. Surg Today. 2021;51(12):1996–9.
doi: 10.1007/s00595-021-02304-7
pubmed: 34009434
Coupaye M, Calabrese D, Sami O, et al. Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(4):681–5.
doi: 10.1016/j.soard.2016.11.022
Pizza F, D’Antonio D, Lucido FS, et al. The role of ursodeoxycholic acid (UDCA) in cholelithiasis management after one anastomosis gastric bypass (OAGB) for morbid obesity: results of a monocentric randomized controlled trial. Obes Surg. 2020;30(11):4315–24.
doi: 10.1007/s11695-020-04801-z
pubmed: 32583297
Sucandy I, Abulfaraj M, Naglak M, et al. Risk of biliary events after selective cholecystectomy during biliopancreatic diversion with duodenal switch. Obes Surg. 2016;26(3):531–7.
doi: 10.1007/s11695-015-1786-4
pubmed: 26156307
Fearon NM, Kearns EC, Kennedy CA, et al. The impact of ursodeoxycholic acid on gallstone disease after bariatric surgery: a meta-analysis of randomized control trials. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2022;18(1):77–84.
doi: 10.1016/j.soard.2021.10.004
Haal S, Guman MSS, de Brauw LM, et al. Cost-effectiveness of ursodeoxycholic acid in preventing new-onset symptomatic gallstone disease after Roux-en-Y gastric bypass surgery. Br J Surg. 2022;109(11):1116–23.
doi: 10.1093/bjs/znac273
pubmed: 35979609
pmcid: 10364680
Hall L, Halle-Smith J, Evans R, Toogood G, Wiggins T, Markar SR, Kapoulas S, Super P, Tucker O, McKay SC. Ursodeoxycholic acid in the management of symptomatic gallstone disease: systematic review and clinician survey. BJS Open. 2023;7(2):zrac152.
doi: 10.1093/bjsopen/zrac152
pubmed: 36952251
pmcid: 10035564
Della Penna A, Lange J, Hilbert J, et al. Ursodeoxycholic acid for 6 months after bariatric surgery is impacting gallstone associated morbidity in patients with preoperative asymptomatic gallstones. Obes Surg. 2019;29(4):1216–21.
doi: 10.1007/s11695-018-03651-0
pubmed: 30604076
Banerjee N, Parepally M, Byrne TK, et al. Systematic review of transgastric ERCP in Roux-en-Y gastric bypass patients. Surg Obes Relat Dis : Off J Am Soc Bariatric Surg. 2017;13(7):1236–42.
doi: 10.1016/j.soard.2017.02.005
Aiolfi A, Asti E, Rausa E, et al. Trans-gastric ERCP after Roux-en-Y gastric bypass: systematic review and meta-analysis. Obes Surg. 2018;28(9):2836–43.
doi: 10.1007/s11695-018-3258-0
pubmed: 29687343